Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 Equity-to-Asset is 0.82 as of Jun. 2026, which is 6% above its 10-year median of 0.77. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,414 Biotechnology companies, SILO Pharma ranks better than 69.31% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. SILO Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $4.89 Mil. SILO Pharma's Total Assets for the quarter that ended in Jun. 2026 was $5.95 Mil.
The historical rank and industry rank for SILO Pharma's Equity-to-Asset or its related term are showing as below:
SILO'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.65 Med: 0.77 Max: 0.94
Current: 0.82
During the past 13 years, the highest Equity to Asset Ratio of SILO Pharma was 0.94. The lowest was -0.65. And the median was 0.77.
SILO's Equity-to-Asset is ranked better than 69.31% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs SILO: 0.82
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
SILO Pharma Equity-to-Asset Related Terms
SILO Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for SILO Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO vs ELAB, GLMD, APVO: Equity-to-Asset Comparison
For the Biotechnology subindustry, SILO Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where SILO Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
SILO Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (SILO) has a Equity-to-Asset of 0.82 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SILO Pharma and its competitors. This is near median its historical median of 0.77. According to the industry distribution chart, SILO Pharma ranks #434 out of 1414 companies in the Biotechnology industry, placing it in the top 30.7%.
Is SILO Pharma's Equity-to-Asset too high?
SILO Pharma's current Equity-to-Asset of 0.82 is near median its 10-year median of 0.77. The Biotechnology industry median Equity-to-Asset is 0.68. SILO Pharma's value of 0.82 is 20.6% above this industry median. Based on the distribution chart, SILO Pharma ranks #434 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's Equity-to-Asset compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #434 out of 1414 companies for Equity-to-Asset. This puts SILO Pharma in the upper half of its industry. The industry median Equity-to-Asset is 0.68. SILO Pharma's value of 0.82 is 20.6% above this benchmark. While the company's 10-year median is 0.77 vs. the industry median of 0.68, SILO Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SILO Pharma's current Equity-to-Asset of 0.82 is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SILO Pharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SILO Pharma's current Equity-to-Asset is 0.82, which is near median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current Equity-to-Asset is 0.82, which is near median its 10-year median of 0.77 and 20.6% above the Biotechnology industry median of 0.68. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For SILO Pharma (SILO), the current Equity-to-Asset is 0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
Equity-to-Asset: 0.82 (near median its 10-year median of 0.77)
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
Industry Position: 20.6% above the Biotechnology median (#434 of 1414)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
